215 related articles for article (PubMed ID: 32899312)
1. OSucs: An Online Prognostic Biomarker Analysis Tool for Uterine Carcinosarcoma.
An Y; Wang Q; Sun F; Zhang G; Wang F; Zhang L; Li Y; Ren W; Zhu W; Li Y; Ji S; Guo X
Genes (Basel); 2020 Sep; 11(9):. PubMed ID: 32899312
[TBL] [Abstract][Full Text] [Related]
2. Identification of distinct molecular subtypes of uterine carcinosarcoma.
An Y; Wang H; Jie J; Tang Y; Zhang W; Ji S; Guo X
Oncotarget; 2017 Feb; 8(9):15878-15886. PubMed ID: 28178664
[TBL] [Abstract][Full Text] [Related]
3. Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity.
Matsuzaki S; Klar M; Matsuzaki S; Roman LD; Sood AK; Matsuo K
Gynecol Oncol; 2021 Feb; 160(2):586-601. PubMed ID: 33183764
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Treatment Modalities, Prognostic Factors, and Outcome of the Uterine Carcinosarcoma.
Kahramanoglu I; Demirkiran F; Turan H; Bese T; Cebi S; Ilvan S; Arvas M
J Obstet Gynaecol Can; 2021 Jan; 43(1):34-42. PubMed ID: 33041218
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronan-mediated motility receptor expression functions as a prognostic biomarker in uterine carcinosarcoma based on bioinformatics analysis.
Sun H; Ma L; Chen J
J Int Med Res; 2021 Jun; 49(6):3000605211021043. PubMed ID: 34111996
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
Harano K; Hirakawa A; Yunokawa M; Nakamura T; Satoh T; Nishikawa T; Aoki D; Ito K; Ito K; Nakanishi T; Susumu N; Takehara K; Watanabe Y; Watari H; Saito T
Int J Clin Oncol; 2016 Feb; 21(1):168-76. PubMed ID: 26084780
[TBL] [Abstract][Full Text] [Related]
7. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
8. Ral GEF with the PH Domain and SH3 Binding Motif 1 Regulated by Splicing Factor Junction Plakoglobin and Pyrimidine Metabolism Are Prognostic in Uterine Carcinosarcoma.
Guo H; Wang S; Xie A; Sun W; Wei C; Xian S; Yin H; Li M; Sun H; Li H; Meng T; Zhang J; Huang Z
Dis Markers; 2021; 2021():1484227. PubMed ID: 34745385
[TBL] [Abstract][Full Text] [Related]
9. Uterine carcinosarcomas: From pathology to practice.
Toboni MD; Crane EK; Brown J; Shushkevich A; Chiang S; Slomovitz BM; Levine DA; Dowdy SC; Klopp A; Powell MA; Thaker PH
Gynecol Oncol; 2021 Jul; 162(1):235-241. PubMed ID: 34030871
[TBL] [Abstract][Full Text] [Related]
10. Whole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine Carcinosarcoma.
Li J; Xing X; Li D; Zhang B; Mutch DG; Hagemann IS; Wang T
Neoplasia; 2017 Feb; 19(2):100-111. PubMed ID: 28088687
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma.
Şükür YE; Taşkın S; Varlı B; Ateş C; Güngör M; Ortaç F
Int J Clin Oncol; 2018 Feb; 23(1):114-120. PubMed ID: 28836024
[TBL] [Abstract][Full Text] [Related]
12. Co-expression Analysis of Genes and Tumor-Infiltrating Immune Cells in Metastatic Uterine Carcinosarcoma.
Huang R; Sun H; Yan G; Zhang L; Sun W; Zhang J; Yin H; Xian S; Hu P; Yan P; Zhu X; Meng T; Wang J; Huang Z
Reprod Sci; 2021 Sep; 28(9):2685-2698. PubMed ID: 33905082
[TBL] [Abstract][Full Text] [Related]
13. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.
Matsuo K; Omatsu K; Ross MS; Johnson MS; Yunokawa M; Klobocista MM; Im DD; Bush SH; Ueda Y; Takano T; Blake EA; Hasegawa K; Baba T; Shida M; Satoh S; Yokoyama T; Machida H; Adachi S; Ikeda Y; Iwasaki K; Miyake TM; Yanai S; Nishimura M; Nagano T; Takekuma M; Takeuchi S; Pejovic T; Shahzad MM; Ueland FR; Kelley JL; Roman LD
Gynecol Oncol; 2017 Apr; 145(1):78-87. PubMed ID: 28215838
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
Zhu J; Wen H; Bi R; Wu X
J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
[TBL] [Abstract][Full Text] [Related]
15. HDAC Inhibition Induces Cell Cycle Arrest and Mesenchymal-Epithelial Transition in a Novel Pleural-Effusion Derived Uterine Carcinosarcoma Cell Line.
Stockhammer P; Okumus Ö; Hegedus L; Rittler D; Ploenes T; Herold T; Kalbourtzis S; Bankfalvi A; Sucker A; Kimmig R; Aigner C; Hegedus B
Pathol Oncol Res; 2021; 27():636088. PubMed ID: 34257602
[No Abstract] [Full Text] [Related]
16. The pan-cancer analysis of the two types of uterine cancer uncovered clinical and prognostic associations with m6A RNA methylation regulators.
Zou Z; Zhou S; Liang G; Tang Z; Li K; Tan S; Zhang X; Zhu X
Mol Omics; 2021 Jun; 17(3):438-453. PubMed ID: 34110327
[TBL] [Abstract][Full Text] [Related]
17. Nestin: A biomarker of aggressive uterine cancers.
Hope ER; Mhawech-Fauceglia P; Pejovic T; Zahn CM; Wang G; Conrads TP; Larry Maxwell G; Hamilton CA; Darcy KM; Syed V
Gynecol Oncol; 2016 Mar; 140(3):503-11. PubMed ID: 26718725
[TBL] [Abstract][Full Text] [Related]
18. RNA-seq Identification of RACGAP1 as a Metastatic Driver in Uterine Carcinosarcoma.
Mi S; Lin M; Brouwer-Visser J; Heim J; Smotkin D; Hebert T; Gunter MJ; Goldberg GL; Zheng D; Huang GS
Clin Cancer Res; 2016 Sep; 22(18):4676-86. PubMed ID: 27121792
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors and status of hormone receptors and angiogenic factors in uterine carcinosarcoma.
Etoh T; Nakai H
J Obstet Gynaecol Res; 2014 Mar; 40(3):820-5. PubMed ID: 24320058
[TBL] [Abstract][Full Text] [Related]
20. Uterine carcinosarcoma vs endometrial serous and clear cell carcinoma: A systematic review and meta-analysis of survival.
Raffone A; Travaglino A; Raimondo D; Maletta M; De Vivo V; Visiello U; Casadio P; Seracchioli R; Zullo F; Insabato L; Mollo A
Int J Gynaecol Obstet; 2022 Sep; 158(3):520-527. PubMed ID: 34797919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]